Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3186 | 0.5008 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3186 | 0.5008 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Plasmodium falciparum | triosephosphate isomerase, putative | 0.0039 | 0.1955 | 0.1318 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0074 | 0.4656 | 0.6639 |
Plasmodium falciparum | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.3186 | 0.5008 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.3186 | 0.2858 |
Mycobacterium ulcerans | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.3186 | 0.5008 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Trypanosoma brucei | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.1286 | 0.0866 |
Schistosoma mansoni | triosephosphate isomerase | 0.0039 | 0.1955 | 0.3073 |
Brugia malayi | Proteasome A-type and B-type family protein | 0.0074 | 0.4656 | 0.4399 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Echinococcus granulosus | proteasome prosome macropain | 0.0074 | 0.4656 | 0.7318 |
Echinococcus multilocularis | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Trypanosoma cruzi | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Treponema pallidum | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0074 | 0.4656 | 0.6639 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0039 | 0.1955 | 0.1318 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Chlamydia trachomatis | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5 |
Brugia malayi | triosephosphate isomerase | 0.0097 | 0.6363 | 0.6187 |
Toxoplasma gondii | triose-phosphate isomerase TPI-I | 0.0097 | 0.6363 | 1 |
Mycobacterium tuberculosis | Probable triosephosphate isomerase Tpi (TIM) | 0.0097 | 0.6363 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0074 | 0.4656 | 0.7318 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0074 | 0.4656 | 0.3868 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0074 | 0.4656 | 0.6639 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.3186 | 0.218 |
Mycobacterium leprae | Probable triosephosphate isomerase Tpi (TIM) | 0.0097 | 0.6363 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Entamoeba histolytica | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Giardia lamblia | Triosephosphate isomerase, cytosolic | 0.0097 | 0.6363 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.3186 | 0.5008 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3186 | 0.5008 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Echinococcus granulosus | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Toxoplasma gondii | triose-phosphate isomerase TPI-II | 0.0097 | 0.6363 | 1 |
Loa Loa (eye worm) | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5826 |
Wolbachia endosymbiont of Brugia malayi | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.3186 | 0.5008 |
Leishmania major | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Schistosoma mansoni | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0074 | 0.4656 | 0.7318 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.7783 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PubChem BioAssay. qHTS for Inhibitors of TGF-b: Confirmation of Cherry Picks. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PubChem BioAssay. qHTS for Inhibitors of TGF-b: Hit Validation in HepG2 Cells using COP promoter. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.